Previously today we heard some comments from Gerald Dal Pan from the U.S. Food and Drug Administration, and my colleague Ms. Davidson,asked about the life-cycle approach.
This is a general question to you and Mr. Ménard. What are your comments on the life-cycle approach? Is that a step in the right direction?